Status:
UNKNOWN
Dexmedetomidine and HIPEC
Lead Sponsor:
University of British Columbia
Conditions:
Inflammation
Cancer
Eligibility:
All Genders
18-99 years
Phase:
PHASE2
PHASE3
Brief Summary
Inflammation is associated with an increased risk of cancer recurrence. Various methods have been used to decrease the inflammatory response induced by the cancer and surgery. In this study the invest...
Detailed Description
Purpose: To investigate the use of intra-operative dexmedetomidine infusions to reduce the inflammatory and stress response of cytoreductive treatment and hyperthermic intra-peritoneal chemotherapy (H...
Eligibility Criteria
Inclusion
- Patients undergoing a Hyperthermic Intraperitoneal Chemotherapy (HIPEC) procedure as part of their cancer treatment at Vancover General Hospital
- 18 years of age or older
- Able to provide informed consent
- Expected stay 5 days or greater in hospital
- Presenting for HIPEC with Colon or Appendix Cancer
Exclusion
- Contraindication to dexmedtomidine use including allergy or sensitivity to the drug
- Pregnancy
- Dementia
- ASA greater than or equal to 4
- Significant liver disease
- Current use of steroid or immunosuppressive medication
- Mesothelioma tumour origin
- Current use of clonidine
- Current opioid use exceeding 30mg of oral morphine equivalents
- Patient not eligible or patient refusal to have a thoracic epidural
Key Trial Info
Start Date :
March 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2024
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04106999
Start Date
March 1 2023
End Date
December 1 2024
Last Update
November 3 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UBC/Medicine, Faculty of/Anesthesiology, Pharmacology & Therapeutics
Vancouver, British Columbia, Canada, V5Z 1L8